Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mohammad Alzrigat

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Oncotarget|January 5, 2017
EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functionsMohammad Alzrigat, Alba Atienza Párraga, Prasoon Agarwal, et al.
Cell Death & Disease|November 16, 2024
EZH2 inhibition sensitizes retinoic acid-driven senescence in synovial sarcomaMuhammad Mushtaq, Judit Liaño-Pons, Jiansheng Wang, et al.
Oncotarget|December 22, 2017
The polycomb group protein BMI-1 inhibitor PTC-209 is a potent anti-myeloma agent alone or in combination with epigenetic inhibitors targeting EZH2 and the BET bromodomainsMohammad Alzrigat, Alba Atienza Párraga, Muntasir Mamun Majumder, et al.
Molecular Pharmaceutics|April 30, 2025
Engineered Peptide Coacervates Enable Efficient Intracellular Delivery of the MYC Inhibitor omoMYCCarmine P Cerrato, Martin Krkoška, Yue Sun, et al.
Nature Communications|November 2, 2022
Publisher Correction: HIF-1 stabilization in T cells hampers the control of Mycobacterium tuberculosis infectionRuining Liu, Victoria Muliadi, Wenjun Mou, et al.
Nature Communications|September 6, 2022
HIF-1 stabilization in T cells hampers the control of Mycobacterium tuberculosis infectionRuining Liu, Victoria Muliadi, Wenjun Mou, et al.
Oncotarget|January 13, 2016
Genome-wide profiling of histone H3 lysine 27 and lysine 4 trimethylation in multiple myeloma reveals the importance of Polycomb gene targeting and highlights EZH2 as a potential therapeutic targetPrasoon Agarwal, Mohammad Alzrigat, Alba Atienza Párraga, et al.
Cancer Research Communications|March 6, 2023
MYCMI-7: A Small MYC-Binding Compound that Inhibits MYC: MAX Interaction and Tumor Growth in a MYC-Dependent MannerAlina Castell, Qinzi Yan, Karin Fawkner, et al.
Cancer Research Communications|March 2, 2023
MYC Inhibition Halts Metastatic Breast Cancer Progression by Blocking Growth, Invasion, and SeedingDaniel Massó-Vallés, Marie-Eve Beaulieu, Toni Jauset, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Oncotarget|January 5, 2017
EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functionsMohammad Alzrigat, Alba Atienza Párraga, Prasoon Agarwal, et al.
Cell Death & Disease|November 16, 2024
EZH2 inhibition sensitizes retinoic acid-driven senescence in synovial sarcomaMuhammad Mushtaq, Judit Liaño-Pons, Jiansheng Wang, et al.
Oncotarget|December 22, 2017
The polycomb group protein BMI-1 inhibitor PTC-209 is a potent anti-myeloma agent alone or in combination with epigenetic inhibitors targeting EZH2 and the BET bromodomainsMohammad Alzrigat, Alba Atienza Párraga, Muntasir Mamun Majumder, et al.
Molecular Pharmaceutics|April 30, 2025
Engineered Peptide Coacervates Enable Efficient Intracellular Delivery of the MYC Inhibitor omoMYCCarmine P Cerrato, Martin Krkoška, Yue Sun, et al.
Nature Communications|November 2, 2022
Publisher Correction: HIF-1 stabilization in T cells hampers the control of Mycobacterium tuberculosis infectionRuining Liu, Victoria Muliadi, Wenjun Mou, et al.
Nature Communications|September 6, 2022
HIF-1 stabilization in T cells hampers the control of Mycobacterium tuberculosis infectionRuining Liu, Victoria Muliadi, Wenjun Mou, et al.
Oncotarget|January 13, 2016
Genome-wide profiling of histone H3 lysine 27 and lysine 4 trimethylation in multiple myeloma reveals the importance of Polycomb gene targeting and highlights EZH2 as a potential therapeutic targetPrasoon Agarwal, Mohammad Alzrigat, Alba Atienza Párraga, et al.
Cancer Research Communications|March 6, 2023
MYCMI-7: A Small MYC-Binding Compound that Inhibits MYC: MAX Interaction and Tumor Growth in a MYC-Dependent MannerAlina Castell, Qinzi Yan, Karin Fawkner, et al.
Cancer Research Communications|March 2, 2023
MYC Inhibition Halts Metastatic Breast Cancer Progression by Blocking Growth, Invasion, and SeedingDaniel Massó-Vallés, Marie-Eve Beaulieu, Toni Jauset, et al.
Pageof 2